Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax plus azacitidine for newly diagnosed CMML
ChiCTR2600133250Phase 4Not yet recruiting
- Sponsor
- Zhenjiang First People's Hospital
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisaftoclax and azacitidine in chronic myelomonocytic leukemia (CMML), sponsored by Zhenjiang First People's Hospital. Primary endpoint: Overall response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lisaftoclaxazacitidine
03
Conditions
chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR2600133250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133250.